Puma Biotechnology (PBYI) Earns Coverage Optimism Rating of 0.22
News headlines about Puma Biotechnology (NYSE:PBYI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Puma Biotechnology earned a news impact score of 0.22 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.230603440835 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern’s analysis:
- Puma Biotechnology Inc (PBYI) Downgraded by BidaskClub (americanbankingnews.com)
- Puma Biotech Stock Offers Opportunity To Cash In On Its Maiden Product Launch (seekingalpha.com)
- Puma Biotechnology Inc (PBYI) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- Puma Biotechnology, Inc. (PBYI) 54.82% off from 200- SMA: Puma Biotechnology, Inc. (PBYI) – Voice Of Analysts (analystsbuzz.com)
- Puma Biotechnology Becomes Oversold (PBYI) (nasdaq.com)
Shares of Puma Biotechnology (NYSE:PBYI) opened at 80.70 on Friday. The firm’s market capitalization is $3.00 billion. Puma Biotechnology has a one year low of $28.35 and a one year high of $98.85. The company has a 50-day moving average price of $87.86 and a 200 day moving average price of $57.72.
Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by $0.78. Analysts expect that Puma Biotechnology will post ($8.62) earnings per share for the current fiscal year.
Several brokerages recently weighed in on PBYI. BidaskClub lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Wednesday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $110.00 target price (down from $118.00) on shares of Puma Biotechnology in a research report on Thursday, August 10th. J P Morgan Chase & Co set a $105.00 target price on Puma Biotechnology and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Leerink Swann reiterated an “outperform” rating and issued a $125.00 price target on shares of Puma Biotechnology in a report on Wednesday, August 2nd. Finally, Cowen and Company reiterated an “outperform” rating and issued a $120.00 price target (up from $91.00) on shares of Puma Biotechnology in a report on Saturday, July 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $109.56.
TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/18/puma-biotechnology-pbyi-earns-coverage-optimism-rating-of-0-22.html.
In related news, insider Alan H. Auerbach sold 13,175 shares of Puma Biotechnology stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total value of $1,248,067.75. Following the transaction, the insider now owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of Puma Biotechnology stock in a transaction on Friday, May 26th. The stock was sold at an average price of $75.38, for a total transaction of $93,147,066.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,010,261 shares of company stock valued at $159,425,452. 22.70% of the stock is owned by company insiders.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.